ETER701
Regimen
- Experimental
- benmelstobart + anlotinib + etoposide + carboplatin (four-drug) vs anlotinib + EC (three-drug)
- Control
- double placebo + etoposide + carboplatin (EC alone)
Population
Treatment-naive extensive-stage small-cell lung cancer (Chinese population)
Key finding
mOS 19.3 vs 11.9 mo for benmelstobart+anlotinib+EC vs EC (HR 0.61, P=0.0002); anlotinib+EC vs EC 13.3 vs 11.9 mo (HR 0.86, P=0.1723, NS)
Source: PMID 38992123
Timeline
Guideline citations
- CSCO SCLC 2025 (p.66)⚠️ OCR source